Molecular subtyping, tumor infiltration, and trimodal therapy for muscle-invasive bladder cancer: more questions than answers
- PMID: 31392159
- PMCID: PMC6642967
- DOI: 10.21037/tau.2019.05.12
Molecular subtyping, tumor infiltration, and trimodal therapy for muscle-invasive bladder cancer: more questions than answers
Conflict of interest statement
Conflicts of Interest: The authors have no conflicts of interest to declare.
Comment on
-
Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.Eur Urol. 2019 Jul;76(1):59-68. doi: 10.1016/j.eururo.2019.01.011. Epub 2019 Feb 1. Eur Urol. 2019. PMID: 30712971 Free PMC article.
References
-
- Fahmy O, Khairul-Asri MG, Schubert T, et al. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer. Urol Oncol 2018;36:43-53. 10.1016/j.urolonc.2017.10.002 - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources